Diprosalic lotion

Land: Armenien

Sprache: Englisch

Quelle: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Wirkstoff:

betamethasone (betamethasone dipropionate), salicylic acid

Verfügbar ab:

Cenexi HSC

ATC-Code:

D07XC01

INN (Internationale Bezeichnung):

betamethasone (betamethasone dipropionate), salicylic acid

Dosierung:

0,5mg/g+ 20mg/g

Darreichungsform:

lotion

Einheiten im Paket:

30ml plastic container-dropper

Verschreibungstyp:

Prescription

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2020-08-04

Fachinformation

1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
DIPROSALIC
®
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_GENERAL CHARACTERISTIC: _
_MAIN PHYSICAL/CHEMICAL PROPERTIES_:
a colourless, translucent, viscous solution, without foreign
inclusion. Can be opalescence.
_COMPOSITION: _
1 g of lotion contains betamethasone 0.5 mg (as dipropionate) and
salicylic acid 20 mg;
_excipients: _
disodium edentate, hydroxypropyl methylcellulose, sodium hydroxide,
isopropyl alcohol,
purified water.
3.
PHARMACEUTICAL FORM
Lotion.
PHARMACOTHERAPEUTIC GROUP.
Dermatological corticosteroids. Active corticosteroids in combination
with other agents. ATC code: D07X C01.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
To relieve inflammation in the psoriasis and seborrheic dermatitis of
scalp, psoriasis of other sites
and dermatoses
accompanied by hyperkeratosis that are normally responsive to
corticosteroid
therapy, except facial seborrheic dermatitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults and children: several drops of lotion should be applied to
cover the affected areas and then be
massaged gently into the skin or scalp. It is usually applied twice
daily – in the morning and in the
evening.
_Duration of therapy_
.
It is recommended that using of lotion 2 times daily should be limited
to one-two weeks; for
maintenance therapy application once daily may be adequate. Increased
frequency of application the
drug may aggravate side effects without increasing therapeutic
efficacy. In some cases application of
one dose daily is adequate. Frequency of application may be reduced
after improvement of disease.
Precautions should be taken if extensive body surface areas are
treated (metering the used drug).
Withdrawal should be done gradually, by increasing interval of dosing
or using less strong or less
dosed corticosteroids, or alternating to the drugs which are not
containing corticosteroids. The period
of application should not exceed three weeks.
Long continuous treatment is not recommended to all patients